Replies to post #413713 on Amarin Corp Plc (AMRN)

[TalShu]

Lizzy

QUOTE"We are excited about the continued adoption of Vascepa and opportunities for future growth, while also acknowledging that the current growth trajectory is not as rapid as originally projected. Our goal moving forward is to invest where we can drive continued growth but with an accelerated timeframe to brand profitability."
Due to payer mix dynamics, public plan reimbursement delays, and slower than expected uptake with general practitioners, HLS is guiding to a 2023 Vascepa revenue range of C$18-20 million compared to the low end of its previously issued C$22-28 million revenue range.UNQUOTE

This doesn't sound good.

[TCI1]

Net revenue is up 49% Q2 2023 v 2022 yet prescriptions are up 91%. Wonder what the reason for this difference is? Distribution timing? Reduction in reimbursement price achieved with provinces versus private insurers (a lot of prior revenue was private insurers). They note slow uptake by GPs - Pfizer are responsible for this area if I remember correctly. Are their reps focused on other drugs. Who knows but revenue growth is disappointing.